VIENNA, Austria — Compared with subcutaneous interferon β-1a (IFNB-1a; Rebif/EMD Serono/Pfizer), treatment with alemtuzumab (Lemtrada, Genzyme/Sanofi) improved visual outcomes in treatment-naive ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The LYNX-2 study is being conducted under conditions of ...
Durable improvement in best-corrected visual acuity (BCVA), as GS010-treated eyes sustain +15.4 ETDRS letters equivalent improvement versus baseline and +28.1 ETDRS letters equivalent versus nadir ...
MR-142 Achieved Primary Endpoint of ≥15-letter (≥3-line) Gain in Mesopic Low Contrast Distance Visual Acuity in Comparison to Placebo Results Showed Patient-Reported Functional Benefit in Treating ...
Please provide your email address to receive an email when new articles are posted on . Despite having reduced high-contrast and glare visual acuity with toric orthokeratology lenses, study ...
"This study aimed to evaluate the equivalence of a smartphone-based visual acuity chart with a standard 6-m Snellen visual acuity (6SVA) chart." Researchers first reviewed Snellen chart apps that were ...
Monocular contrast sensitivity and microperimetry are useful indicators of visual function and its impact on activities of daily living in those with AMD. Patients with AMD do not rely on binocular ...
The Fast Track designation is supported by the ongoing randomized, double-masked phase 3 LYNX-2 trial. The Food and Drug Administration (FDA) has granted Fast Track designation to phentolamine ...
PITTSBURGH, June 2, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced positive top-line results from LYNX-2, a pivotal Phase 3 trial evaluating MR-142 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback